Aza- and polyaza-naphthalenyl carboxamide derivatives including certain quinoline carboxamide and naphthyridine carboxamide derivatives are described. These compounds are inhibitors of HIV integrase and inhibitors of HIV replication, and are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, as compounds or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described.
L'invention concerne des dérivés d' aza-naphtalényle carboxamide et de polyaza-naphtalényle carboxamide comprenant certains dérivés de quinoline carboxamide et de naphtyridine carboxamide. Ces composés sont des inhibiteurs de l'intégrase du VIH et des inhibiteurs de réplication du VIH et sont utiles pour la prévention ou le traitement d'infections à VIH et le traitement du SIDA, en tant que composés ou sels pharmaceutiquement acceptables, ou en tant qu'ingrédients dans des compositions pharmaceutiques, éventuellement combinés à d'autres antiviraux, immunomodulateurs, antibiotiques ou vaccins. L'invention concerne également des méthodes permettant de prévenir, de traiter ou de retarder l'apparition du SIDA ainsi que des méthodes permettant de prévenir ou de traiter une infection à VIH.




Download Full PDF Version (Non-Commercial Use)

Patent Citations (2)

    Publication numberPublication dateAssigneeTitle
    WO-9625399-A1August 22, 1996The United States Of America, Represented By The Secretary, Department Of Health And Human Services, Georgia Tech Research CorporationNovel aroylaniline derivatives, compositions and uses thereof in the treatment of viral infections
    WO-9811073-A1March 19, 1998Pharmacia & Upjohn Company8-hydroxy-7-substituted quinolines as anti-viral agents

NO-Patent Citations (0)


Cited By (2)

    Publication numberPublication dateAssigneeTitle
    US-9284275-B2March 15, 2016Critical Outcome Technologies Inc.Inhibitor compounds and cancer treatment methods
    US-9422282-B2August 23, 2016Critical Outcome Technologies Inc.Compounds and method for treatment of HIV